As part of CRA’s issues leadership initiative to challenge industry thinking on rare diseases, we assembled a panel of CRA experts to discuss the opportunities and challenges posed by the latest therapeutic breakthroughs in conditions that affect fewer than one in 2,000 people. Neil Turner moderates a discussion with Greg Bell, Kevin Brubacher, Ned Kitfield, Cécile Matthews, and Tim Wilsdon.
World Orphan Drug Congress Europe 2024 Review: 3 Themes for sustainable and equitable access to medicines for RD patients
This year’s European World Orphan Drug Congress, attended by CRA’s Bhavesh Patel, Michele Pistollato, Charlotte Poon, Owen Male and Clara Zacharko in...